Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 9 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

56%

5 trials in Phase 3/4

Results Transparency

0%

0 of 4 completed trials have results

Key Signals

1 recruiting

Enrollment Performance

Analytics

Phase 4
5(83.3%)
Phase 1
1(16.7%)
6Total
Phase 4(5)
Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (9)

Showing 9 of 9 trials
NCT05939167Phase 1Recruiting

Mesenchymal Stem Cells Treatment for AIDS Patients at Late Stage

Role: collaborator

NCT05538546Unknown

Baveno VI Criteria in Dynamic Monitoring of High-risk Varices in Compensated Cirrhotic Patients

Role: collaborator

NCT04907981Completed

Eye Detection to Identify Novel Coronavirus Infection

Role: collaborator

NCT02241616Phase 4Unknown

Traditional Chinese Medicine Combined With Entecavir to Treat Refractory Liver Fibrosis in Liver Cirrhosis Due to HBV

Role: collaborator

NCT02241590Phase 4Unknown

Treatment of Liver Cirrhosis Due to Hepatitis B Virus With Fuzheng Huayu and Entecavir

Role: collaborator

NCT01943617Phase 4Completed

Optimized Treatment and Regression of HBV-induced Compensated Liver Cirrhosis

Role: collaborator

NCT01938820Phase 4Completed

Optimized Treatment and Regression of HBV-induced Early Cirrhosis

Role: collaborator

NCT01938781Phase 4Completed

Optimized Treatment and Regression of HBV-induced Liver Fibrosis

Role: collaborator

NCT03108794Unknown

A Nation-wide Hospital-based Hepatitis B Registry:China Registry of Hepatitis B

Role: collaborator

All 9 trials loaded